Abstract
Purpose Gangliosidoses are a group of inherited neurogenetic autosomal recessive lysosomal storage disorders usually presenting with progressive macrocephaly, developmental delay and regression, leading to significant morbidity, and premature death. A quantitative definition of the natural history would support and enable clinical development of specific therapies.
Methods Single disease registry of eight gangliosidoses (NCT04624789).
Cross-sectional analysis of baseline data in N= 26 patients.
Primary endpoint: disease severity assessed by the 8-in-1 score.
Secondary endpoints: first neurological sign or symptom observed a. by parents and b. by physicians, diagnostic delay, as well as phenotypical characterization.
Tertiary endpoints: Neurological outcomes (development, ataxia, dexterity) and disability.
Results The 8-in-1 score quantitatively captured severity of disease. Parents recognized initial manifestations (startle reactions) earlier than physicians (motor developmental delay and hypotonia). Median diagnostic delay was 3.16 [IQR 0.69 … 6.25] years. Eight patients presented with late-infantile phenotypes.
Conclusion Data in this registry raise awareness of these rare and fatal conditions in order to accelerate diagnosis, inform counselling of afflicted families, define quantitative endpoints for clinical trials, and can serve as historical controls for future therapeutic studies. The characterization of a late-infantile phenotype is novel. Longitudinal follow-up is planned.
Competing Interest Statement
Dr. Ries declares no conflict of interest. Dr. Mendoza declares no conflict of interest. Dr. Arash-Kaps declares no conflict of interest. Mr. Quack is a volunteering member the patients' organization "Hand in Hand against Tay-Sachs and Sandhoff disease" who financially supported this study. Mrs. Hardt is a volunteering member the patients' organization "Hand in Hand against Tay-Sachs and Sandhoff disease" who financially supported this study. Dr. Amraoui declares no conflict of interest. Dr. Beck received honoraria from Takeda. Dr. Mengel received research grants and consultation fees and speakers' honoraria from Sanofi Genzyme, Amicus, Takeda, Orphazyme, Prevail, Idorsia, Sio and Taysha.
Funding Statement
This study was jointly funded by the patients' advocacy organization “Hand in Hand e.V.” and the independent non-profit clinical research organization "SphinCS Lyso gemeinnuetzige UG".
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the state medical board Hessen, Frankfurt, Germany (registration number 2019-1483-evBO) and registered on clinicaltrials.gov (NCT04624789). All parents, caregivers, or patients signed informed consent or, if applicable, assent before inclusion into the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Registered under clinicaltrials.gov No. NCT04624789
Conflict of Interest Notification Page Dr. Ries declares no conflict of interest.
Dr. Mendoza declares no conflict of interest.
Dr. Arash-Kaps declares no conflict of interest.
Mr. Quack is a volunteering member the patients’ organization “Hand in Hand against Tay-Sachs and Sandhoff disease” who financially supported this study.
Mrs. Hardt is a volunteering member the patients’ organization “Hand in Hand against Tay-Sachs and Sandhoff disease” who financially supported this study.
Dr. Amraoui declares no conflict of interest.
Dr. Beck received honoraria from Takeda.
Dr. Mengel received research grants and consultation fees and speakers’ honoraria from Sanofi Genzyme, Amicus, Takeda, Orphazyme, Prevail, Idorsia, Sio and Taysha.
Data Availability
All data produced in the present study are available upon reasonable request to the author
